Market Cap 6.91B
Revenue (ttm) 39.21M
Net Income (ttm) -311.35M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -794.06%
Debt to Equity Ratio 0.00
Volume 688,800
Avg Vol 792,524
Day's Range N/A - N/A
Shares Out 81.64M
Stochastic %K 10%
Beta 2.20
Analysts Strong Sell
Price Target $119.71

Company Profile

Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing KT-621, an oral STAT6 degrader in Phase 2b clinical trials for moderate to severe atopic dermatitis, asthma, COPD, EoE, CRSwNP, CSU, PN, BP, and others; KT-579, an oral IRF5 degrader in Phase 1 trials for autoimmune disease...

Industry: Biotechnology
Sector: Healthcare
Phone: 857 285 5300
Address:
500 North Beacon Street, 4th Floor, Watertown, United States
prismmarketview
prismmarketview Mar. 10 at 4:21 PM
Kymera Therapeutics (NASDAQ: $KYMR) is showcasing Phase 1b data for oral STAT6 degrader KT‑621 at the AAD 2026 meeting, highlighting deep ≥94–98% STAT6 degradation in skin and blood, strong Type‑2 biomarker reductions, and meaningful EASI and itch improvements in moderate‑to‑severe atopic dermatitis, with a clean safety profile backing upcoming Phase 2b AD and asthma trials. https://prismmarketview.com/kymera-therapeutics-presents-phase-1b-data-for-kt-621-at-aad-meeting/
0 · Reply
IN0V8
IN0V8 Mar. 3 at 8:48 PM
$KYMR Buy UBS raises target price to $128 from $90
1 · Reply
erevnon
erevnon Mar. 3 at 8:16 PM
UBS maintains Kymera Therapeutics $KYMR at Buy and raises the price target from $90 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Mar. 2 at 7:38 PM
$KYMR RSI: 72.14, MACD: 4.3166 Vol: 5.79, MA20: 84.18, MA50: 78.97 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
redenergy
redenergy Feb. 26 at 11:13 PM
$KYMR on our radar now: https://trialradar.com/c/KYMR
0 · Reply
erevnon
erevnon Feb. 26 at 6:17 PM
Piper Sandler maintains Kymera Therapeutics $KYMR at Overweight and raises the price target from $125 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
MikeyNJ
MikeyNJ Feb. 26 at 4:39 PM
$KYMR Piper raises price target to $140.
0 · Reply
Dkll303
Dkll303 Feb. 26 at 2:31 PM
$KYMR a true fcuking joke ..almost like a Trump Org !!! Smoke and mirrors and only 1.6B … Hell , the misfits down the street in Cambridge, Ma. At $AGIO , have 1.3B , with drug approvals , but they are misfits and so, $29 ..hahaha and this pos is at $80+ And AGIO, filed for a mixed shelf offering with revenue of 19M a quarter…so, who is blowing who, in the back room of KYMR ??? At AGIO..they just LIE !
0 · Reply
Dkll303
Dkll303 Feb. 26 at 2:28 PM
$KYMR About time…they are light years away from any product
0 · Reply
OpenOutcrier
OpenOutcrier Feb. 26 at 1:35 PM
$KYMR (-6.8% pre) Kymera Therapeutics GAAP EPS of -$0.97 misses by $0.18, revenue of $2.9M misses by $11.9M https://ooc.bz/l/94790
0 · Reply
Latest News on KYMR
Kymera Therapeutics Announces Proposed Public Offering

Dec 8, 2025, 4:01 PM EST - 3 months ago

Kymera Therapeutics Announces Proposed Public Offering


This Drugmaker's Stock Is Soaring Over 40% Monday

Dec 8, 2025, 3:50 PM EST - 3 months ago

This Drugmaker's Stock Is Soaring Over 40% Monday


Kymera's KT-621 Shines: Phase 1b Data Boosts Momentum

Dec 8, 2025, 9:15 AM EST - 3 months ago

Kymera's KT-621 Shines: Phase 1b Data Boosts Momentum


The Best Small-Cap Stocks to Buy Now

Aug 12, 2025, 9:47 AM EDT - 7 months ago

The Best Small-Cap Stocks to Buy Now

DNLI WAY


Kymera Therapeutics Announces Sanofi IRAK4 Collaboration Update

Jun 25, 2025, 7:05 AM EDT - 9 months ago

Kymera Therapeutics Announces Sanofi IRAK4 Collaboration Update


prismmarketview
prismmarketview Mar. 10 at 4:21 PM
Kymera Therapeutics (NASDAQ: $KYMR) is showcasing Phase 1b data for oral STAT6 degrader KT‑621 at the AAD 2026 meeting, highlighting deep ≥94–98% STAT6 degradation in skin and blood, strong Type‑2 biomarker reductions, and meaningful EASI and itch improvements in moderate‑to‑severe atopic dermatitis, with a clean safety profile backing upcoming Phase 2b AD and asthma trials. https://prismmarketview.com/kymera-therapeutics-presents-phase-1b-data-for-kt-621-at-aad-meeting/
0 · Reply
IN0V8
IN0V8 Mar. 3 at 8:48 PM
$KYMR Buy UBS raises target price to $128 from $90
1 · Reply
erevnon
erevnon Mar. 3 at 8:16 PM
UBS maintains Kymera Therapeutics $KYMR at Buy and raises the price target from $90 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Mar. 2 at 7:38 PM
$KYMR RSI: 72.14, MACD: 4.3166 Vol: 5.79, MA20: 84.18, MA50: 78.97 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
redenergy
redenergy Feb. 26 at 11:13 PM
$KYMR on our radar now: https://trialradar.com/c/KYMR
0 · Reply
erevnon
erevnon Feb. 26 at 6:17 PM
Piper Sandler maintains Kymera Therapeutics $KYMR at Overweight and raises the price target from $125 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
MikeyNJ
MikeyNJ Feb. 26 at 4:39 PM
$KYMR Piper raises price target to $140.
0 · Reply
Dkll303
Dkll303 Feb. 26 at 2:31 PM
$KYMR a true fcuking joke ..almost like a Trump Org !!! Smoke and mirrors and only 1.6B … Hell , the misfits down the street in Cambridge, Ma. At $AGIO , have 1.3B , with drug approvals , but they are misfits and so, $29 ..hahaha and this pos is at $80+ And AGIO, filed for a mixed shelf offering with revenue of 19M a quarter…so, who is blowing who, in the back room of KYMR ??? At AGIO..they just LIE !
0 · Reply
Dkll303
Dkll303 Feb. 26 at 2:28 PM
$KYMR About time…they are light years away from any product
0 · Reply
OpenOutcrier
OpenOutcrier Feb. 26 at 1:35 PM
$KYMR (-6.8% pre) Kymera Therapeutics GAAP EPS of -$0.97 misses by $0.18, revenue of $2.9M misses by $11.9M https://ooc.bz/l/94790
0 · Reply
StocktwitsEarnings
StocktwitsEarnings Feb. 26 at 12:17 PM
$KYMR Q4 '25 Earnings Results & Recap • Reported GAAP EPS of -$0.97 down -10.23% YoY • Reported revenue of $2.87M down -61.17% YoY • Kymera Therapeutics expects its $1.6B cash, cash equivalents, and investments as of December 31, 2025, to provide a cash runway into 2029, supporting multiple clinical inflection points in its pipeline.
0 · Reply
BillionerOfKing
BillionerOfKing Feb. 12 at 6:46 PM
$KYMR Current Stock Price: $84.63 Contracts to trade: $85.0 KYMR Feb 20 2026 Call Entry: $1.70 Exit: $2.22 ROI: 31% Hold ~23 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
cheruskian
cheruskian Feb. 12 at 9:25 AM
$KYMR I'm writing both ways options at this level.
0 · Reply
SuperGreenToday
SuperGreenToday Feb. 10 at 8:09 PM
$KYMR Share Price: $79.44 Contract Selected: Aug 21, 2026 $95 Calls Buy Zone: $4.93 – $6.09 Target Zone: $9.16 – $11.20 Potential Upside: 76% ROI Time to Expiration: 191 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
Quantumup
Quantumup Feb. 10 at 5:21 PM
William Blair⬆️ $NKTR to Outperform and provided its Take and Stock Thoughts. $CRVS $REGN - SNY $APGE $KYMR William Blair said: Rezpeg, continues to demonstrate deepening of response and durability with longer-term data—Re: durability, WB noted, there appears to be no meaningful deterioration of response when comparing the monthly dosing to the quarterly dosing—noted, there were no reported cases of conjunctivitis, erythema, oral ulcers, cardiovascular adverse events, or malignancies in the Phase 2 REZOLVE-AD study of rezpeg. Here's what else William Blair had to say: https://x.com/Quantumup1/status/2021272497862115591?s=20
0 · Reply
stu4
stu4 Feb. 9 at 9:19 PM
$CADL …blah blah…immunology has been going on for years …this company is years behind others especially in prostate cancer , therapies exist !!! DAH ….and are working The rest of the BS here is hype , or this would be at $79 along with $KYMR , or $ARWR ….but instead is running a close 2nd behind $IMNN , hahaha
2 · Reply
SuperGreenToday
SuperGreenToday Feb. 2 at 1:14 PM
$KYMR Share Price: $72.73 Contract Selected: Aug 21, 2026 $95 Calls Buy Zone: $4.74 – $5.86 Target Zone: $8.78 – $10.73 Potential Upside: 75% ROI Time to Expiration: 199 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
cheruskian
cheruskian Feb. 1 at 9:29 AM
$KYMR the way the market is trading biotech these days we are probably going to see the 60s again here.
0 · Reply
ZacksResearch
ZacksResearch Jan. 30 at 4:01 PM
$KYMR surges 68.9% in 6 months — what's driving the rally? The phase IIb BREADTH study for KT-621 in eosinophilic asthma marks a key step forward for developing oral treatments for type II inflammatory diseases, with top-line data expected in late 2027. Plus, KYMR holds a Zacks Rank #2 (Buy), signaling strong potential. See what makes the investment case strong for Kymera here 👉 https://www.zacks.com/stock/news/2826252/kymr-initiates-dosing-in-mid-stage-asthma-study-of-lead-candidate?cid=sm-stocktwits-2-2826252-body-31192&ADID=SYND_STOCKTWITS_TWEET_2_2826252_BODY_31192
0 · Reply
ZacksResearch
ZacksResearch Jan. 30 at 2:18 PM
$KYMR just hit a key clinical milestone — this is one to watch Kymera Therapeutics has initiated phase IIb dosing of its oral lead candidate KT-621 in eosinophilic asthma, targeting STAT6, with top-line BREADTH study data expected in late 2027. Progress like this keeps the pipeline narrative alive. See the full study details here 👉 https://www.zacks.com/stock/news/2826252/kymr-initiates-dosing-in-mid-stage-asthma-study-of-lead-candidate?cid=sm-stocktwits-2-2826252-teaser-31162&ADID=SYND_STOCKTWITS_TWEET_2_2826252_TEASER_31162
0 · Reply
SuperGreenToday
SuperGreenToday Jan. 30 at 12:50 PM
$KYMR Share Price: $73.91 Contract Selected: Aug 21, 2026 $95 Calls Buy Zone: $4.74 – $5.86 Target Zone: $8.79 – $10.75 Potential Upside: 75% ROI Time to Expiration: 202 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
MikeyNJ
MikeyNJ Jan. 28 at 3:08 PM
$KYMR Barclay's raises price target from $119 to $133. Amazing!
0 · Reply